Provides relative to health insurance policies providing prescription drug coverage. (8/1/14)
Impact
The legislation specifically focuses on providing coverage for drugs prescribed for chronic illnesses when these are dispensed according to a synchronized plan developed collaboratively by the patient, healthcare practitioner, and pharmacist. Additionally, the bill seeks to standardize the way dispensing fees are calculated, disallowing payment structures that use prorated dispensing fees based on the daily supply of medication. This change is anticipated to alleviate some financial burdens on patients by ensuring that they are not penalized for receiving medications in smaller quantities that align better with their health management strategies.
Summary
Senate Bill 182, introduced by Senator Mills, aims to enhance health insurance policies regarding prescription drug coverage. The bill mandates that health insurance plans allow for the application of prorated daily cost-sharing rates for prescriptions filled for less than a thirty-day supply, particularly when such action is in the patient's best interest or part of a synchronization strategy for existing medications. This provision is designed to improve medication adherence and optimize treatment outcomes for patients who manage chronic conditions.
Sentiment
Overall, the sentiment surrounding SB 182 appears to be positive among healthcare providers and patient advocacy groups, who argue that enhancing access to prescription drugs and aligning medication dispensing practices with patient needs is crucial for treating chronic illnesses effectively. However, there may be concerns from insurance companies regarding potential cost implications that could arise from the mandated coverage and fee structures.
Contention
While SB 182 advocates emphasize the flexibility and benefits for patient care, opponents may voice apprehensions regarding how the bill could impact insurer operations and the broader consequences on healthcare costs. Further debates are likely to arise concerning the implementation of these new guidelines and their practical repercussions for both healthcare providers and insurance companies.
Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.